Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice

Cancer Medicine
Joanna Rupa-MatysekMieczysław Komarnicki

Abstract

The utility in clinical practice of a recently developed and validated predictive model for venous thromboembolism (VTE) events in lymphoma patients, known as the thrombosis lymphoma (ThroLy) score, is unknown. We evaluated the association of ThroLy with VTE in patients treated for diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) undergoing ambulatory first-line chemotherapy. Retrospective analyses were performed on 428 patients (median age 50), 241 were newly diagnosed DLBCL, and 187 had HL. During initial chemotherapy, 64 (15%) patients developed VTE. According to the ThroLy, 322 (75.2%) patients were considered low risk, 88 (20.6%) patients had intermediate risk and 18 (4.2%) patients high risk for VTE development. Patients with DLBCL were more often in the high-risk ThroLy group and had more VTE events than HL. VTE occurred in; 38.9% (n = 7) high-risk patients, 29.5% (n = 26) intermediate risk, and 9.6% (n = 31) low risk according to the ThroLy score. However, in multivariate analysis, high ThroLy (OR 5.13; 95% CI: 1.83-14.36, P = .002), intermediate ThroLy (OR 3.96; 95% CI: 2.19-7.17, P < .001), and aggressive lymphoma-DLBCL (OR 1.91; 95% CI: 1.05-3.47, P = .034) were all significantly associated with develop...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Aug 12, 2005·Current Opinion in Hematology·Haruka Itakura
Feb 27, 2007·Journal of Thrombosis and Haemostasis : JTH·A A KhoranaG H Lyman
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna Falanga, Marina Marchetti
Sep 11, 2010·Blood·Cihan AyIngrid Pabinger
Dec 4, 2010·Thrombosis Research·Danijela LekovicBiljana Mihaljevic
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MandalàUNKNOWN ESMO Guidelines Working Group
Jan 26, 2012·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Sylvia K HaasUNKNOWN TOPIC Investigators
Feb 18, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN SAVE-ONCO Investigators
Aug 3, 2013·Blood·Jasmijn F TimpSuzanne C Cannegieter
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanUNKNOWN American Society of Clinical Oncology
Mar 13, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Sung Hee LimSeok Jin Kim
Apr 24, 2015·Thrombosis Research·Anna FalangaLaura Russo
May 20, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Uwe PelzerHanno Riess
Jul 28, 2015·The Keio Journal of Medicine·Kenji Yokoyama
Jul 7, 2016·American Journal of Hematology·Darko AnticBiljana Mihaljevic
Mar 16, 2017·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Y WangA J Tafur
Aug 16, 2017·Blood·Yohei Hisada, Nigel Mackman
Sep 18, 2017·Critical Reviews in Oncology/hematology·Anna FalangaAlfonso Vignoli

❮ Previous
Next ❯

Citations

Jun 11, 2021·Seminars in Thrombosis and Hemostasis·Matteo CandeloroMarcello Di Nisio
Oct 1, 2021·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Hikmat Abdel-RazeqMais Zmaily
Oct 2, 2021·Cancer Medicine·Mariana Bastos-OreiroCristina Pascual Izquierdo

❮ Previous
Next ❯

Software Mentioned

STATISTICA
ThroLy

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.